X-ray of hips showing narrowing of joint space, osteophyte production and increased density of bone end. Credit: Wellcome Photo Library. Wellcome Images.

Flexion Therapeutics has enrolled the first patient in a Phase III clinical trial to examine the safety and efficacy of zilretta (triamcinolone acetonide extended-release injectable suspension) for the treatment of patients with hip osteoarthritis (OA).

Hip OA is a degenerative disease with no cure that is estimated to affect nearly a quarter of the US population in their lifetime.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Flexion aims to enrol 440 patients with hip OA pain as part of the double-blind, placebo-controlled trial.

Patients will be randomised in 1:1 ratio into one of two treatment groups to receive a single intra-articular (IA) injection of either zilretta or placebo.

After being treated with the first injection of zilretta or placebo, patients will be assessed at weeks 12, 16, 20 and 24 to determine the clinical requirement of a second IA injection.

“We believe zilretta may be able to play an important role in helping these patients find meaningful pain relief.”

Patients eligible for a second injection will be treated with open-label zilretta at the time of recurrent symptoms before being monitored for 12 weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The remaining patients who will not receive a second injection will be observed for up to 24 weeks after their first injection.

Primary objective of the trial is the scale of pain relief against placebo as assessed by the Western Ontario and McMaster Universities Osteoarthritis Index A (WOMAC A) subscale at week 12.

Flexion Therapeutics president and CEO Michael Clayman said: “Like OA of the knee, OA of the hip is a serious disease that can profoundly affect one’s quality of life.

“These impacts are compounded by the fact that there are so few non-surgical treatment options available to manage OA hip pain, and we believe zilretta may be able to play an important role in helping these patients find meaningful pain relief.

“We look forward to reporting the Phase III results with the expectation that the trial will read out in 2020.”

Flexion also intends to begin new Phase II studies of zilretta later this year.